CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Optical Coherence Tomography-Guided Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Prospective Propensity-Matched Cohort of the Thrombectomy Versus Percutaneous Coronary Intervention Alone Trial Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Intravascular optical coherence tomography Anatomical Attributes of Clinically Relevant Diagonal Branches in Patients with Left Anterior Descending Coronary Artery Bifurcation Lesions Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial Chronic thromboembolic pulmonary hypertension Lesion-Specific and Vessel-Related Determinants of Fractional Flow Reserve Beyond Coronary Artery Stenosis The Relation Between Optical Coherence Tomography-Detected Layered Pattern and Acute Side Branch Occlusion After Provisional Stenting of Coronary Bifurcation Lesions

Original Research25 April 2019

JOURNAL:Eur Heart J. Article Link

Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study

A Ghimire, N Fine, FA McAlister et al. Keywords: echocardiography; epidemiology; heart failure; ejection fraction; HFrecEF

ABSTRACT


AIMS - To identify variables predicting ejection fraction (EF) recovery and characterize prognosis of heart failure (HF) patients with EF recovery (HFrecEF).


METHODS AND RESULTS - RETROSPECTIVE study of adults referred for 2 echocardiograms separated by 6 months between 2008 and 2016 at the two largest echocardiography centres in Alberta who also had physician-assigned diagnosis of HF. Of 10 641 patients, 3124 had heart failure reduced ejection fraction (HFrEF) (EF40%) at baseline: while mean EF declined from 30.2% on initial echocardiogram to 28.6% on the second echocardiogram in those patients with persistent HFrEF (defined by <10% improvement in EF), it improved from 26.1% to 46.4% in the 1174 patients (37.6%) with HFrecEF (defined by EF absolute improvement 10%). On multivariate analysis, female sex [adjusted odds ratio (aOR) 1.66, 95% confidence interval (CI) 1.401.96], younger age (aOR per decade 1.16, 95% CI 1.091.23), atrial fibrillation (aOR 2.00, 95% CI 1.682.38), cancer (aOR 1.52, 95% CI 1.032.26), hypertension (aOR 1.38, 95% CI 1.181.62), lower baseline ejection fraction (aOR per 1% decrease 1.07 (1.061.08), and using hydralazine (aOR 1.69, 95% CI 1.192.40) were associated with EF improvements 10%. HFrecEF patients demonstrated lower rates per 1000 patient years of mortality (106 vs. 164, adjusted hazard ratio, aHR 0.70 [0.620.79]), all-cause hospitalizations (300 vs. 428, aHR 0.87 [0.790.95]), all-cause emergency room (ER) visits (569 vs. 799, aHR 0.88 [0.810.95]), and cardiac transplantation or left ventricular assist device implantation (2 vs. 10, aHR 0.21 [0.100.45]) compared to patients with persistent HFrEF. Females with HFrEF exhibited lower mortality risk (aHR 0.94 [0.880.99]) than males after adjusting for age, time between echocardiograms, clinical comorbidities, medications, and whether their EF improved or not during follow-up.


CONCLUSION - HFrecEF patients tended to be younger, female, and were more likely to have hypertension, atrial fibrillation, or cancer. HFrecEF patients have a substantially better prognosis compared to those with persistent HFrEF, even after multivariable adjustment, and female patients exhibit lower mortality risk than men within each subgroup (HFrecEF and persistent HFrEF) even after multivariable adjustment.